Evicenter
MarkdownMedical informationP&T meetings
Onvuzosiran (ADX-324)

Prophylaxis of hereditary angioedema attacks

Launch
Not announced
Last updated
119 sources

Clinical evidence

ADX-324-101

81 evidence topics · 14 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Registry interventions
Part A: weight-based cohorts in the pharmacokinetic figure
Study outcomes
Rationale for using adverse event incidence as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Part A: participants by total dose group in the pharmacodynamic figure
Total dose groupGroup as printed
Placebo“ph1, 0 mg (n=11)”
Above 0 to 100 mg“ph1, >0-100 mg (n=13)”
Above 100 to 200 mg“ph1, >100-200 mg (n=8)”
Above 200 to 250 mg“ph1, >200-250 mg (n=6)”
Above 250 to 300 mg“ph1, >250-300 mg (n=3)”
Above 300 to 350 mg“ph1, >300-350 mg (n=4)”
Above 350 mg“ph1, >350 mg (n=4)”
300 mg plus or minus 25 mg“ADX-324 300 mg +/- 25 mg (n=5)”
Description of analysis sets
Results
Participant disposition
Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

Part A enrolled healthy volunteers aged 18 to 55 years with a body mass index of 18 to 30 kg/m2, so its pharmacodynamic and safety findings come from a population without HAE. Its dose groups were small: the AAAAI poster lists 3 to 13 participants per total dose group, 5 participants in the 300 mg plus or minus 25 mg group, and the prospectus reports the 6 mg/kg results for 4 participants, 3 of whom were below LLOQ at nadir.

Part B was open-label and uncontrolled and enrolled 3 participants, one of whom withdrew for administrative reasons. Its doses (122.5 mg or 245 mg every 6 months) differ from the phase 3 regimens of 300 mg every 6 months and 240 mg every 3 months. All phase 2a dosing was every 6 months, and the November 2026 presentation describes the 3-month attack-free result as an “Observed 100% Q3M attack-free rate in Phase 2a after the first dose”.

No baseline characteristics, baseline attack rates, on-treatment attack rates, or quality-of-life results were identified. Efficacy is reported as attack-free intervals of individual participants and as an association between attacks and the degree of prekallikrein-kallikrein reduction, and the prospectus figure marks the approximate time of full inhibition (about Day 22) and the point 3 months after the first dose. The proposed threshold differs between documents: “> 70%” in the workshop abstract and “>80%” in the prospectus and other sponsor documents.

The results are available only in congress abstracts, posters, press releases, a corporate presentation, and SEC filings. No peer-reviewed full article was identified, the registry record shows “No Results Posted”, and primary completion is estimated for 2027-12-31. The documents use data cutoffs from December 2024 to November 2026.

The documents report different numbers for Part A: 43 participants (32 onvuzosiran, 11 placebo) in 5 cohorts in the February 2026 release; 49 participants (38 onvuzosiran, 11 placebo) in the posters and the prospectus; and 5, 6, or 7 cohorts in different documents. The prospectus attributes the 94% nadir and 84% six-month reductions to the 6 mg/kg cohort, while the November 2026 presentation attributes them to 6 mg/kg on one page and to 300 mg plus or minus 25 mg on another. The first Part B dose is written as 122 mg, 122.5 mg, or approximately 125 mg.

Safety reporting gives one frequency, 28.9%, attached to headache and injection-site reaction in Part A, and no counts for creatine phosphokinase changes or liver enzyme increases. Serious adverse events are described variously as absent, absent when treatment-related, or absent when drug-related. No immunogenicity data and no electrocardiogram results were identified, although electrocardiogram change is a registry primary outcome.